尼罗丁尼:破坏MYC-MAX异构复合体的作用
Kamilla Shah1, Maham Ansari1, Samina Saeed1
1Department of Biotechnology, Faculty of Life Sciences & Informatics, Balochistan University of Information Technology, Engineering and Management Sciences (BUITEMS), Quetta, Pakistan.
Bioinformatics and biology insights
|July 31, 2024
概括
研究人员重新设计了氨酸激酶抑制剂尼罗丁尼,以准MYC-MAX促进癌症的相互作用. 这种药物稳定了MYC,抑制了驱动癌症的基因表达,并为侵袭性癌症提供了新的治疗途径.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- MYC是细胞平衡的关键转录因子;它的失调驱动了侵略性的癌症.
- MYC-MAX异构体促进瘤发生,但针对这种与小分子的相互作用是具有挑战性的.
- MYC的"无药"地位源于其不稳定的蛋白质结构,需要新的治疗策略.
研究的目的:
- 使用计算机辅助方法探索药物重定向以抑制c-MYC-MAX相互作用.
- 确定现有的药物,可以稳定MYC并破坏其致癌功能.
- 评估尼罗丁尼作为一种潜在的治疗药物来对抗MYC驱动的癌症.
主要方法:
- 利用计算机辅助药物设计,包括对药物银行图书馆的虚拟选.
- 采用基于结构 (AutoDock Vina,Glide) 和基于活动 (QSPR模型) 的选方法.
- 进行了分子动态模拟和基因表达分析,以验证药物向相互作用.
主要成果:
- 确定了c-MYC上可使用药物的网站,并选了DrugBank的化合物,专注于前2%的命中.
- 尼罗丁尼是一种氨酸激酶抑制剂 (TKI),成为一个有前途的候选者,稳定了MYC及其与MAX的相互作用.
- 尼罗丁尼诱导了一种基因表达特征,其中一半的基因是c-MYC-响应的,这表明有针对性的抑制.
结论:
- 尼罗丁尼通过稳定MYC蛋白来证明作为MYC驱动癌症的治疗剂的潜力.
- 这项研究为进一步 in vitro 和 in vivo 验证尼洛尼的疗效提供了基础.
- 药物重新定位提供了一种可行的策略,以向以前"不可药化"的coproteins,如MYC.
相关概念视频
Induced Pluripotent Stem Cells
4.0K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.0K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Canonical Wnt Signaling Pathway
8.7K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.7K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K


